Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus POLYMOX.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic